The Fort Worth Press - Frenchman rewarded for lifetime of research into narcolepsy

USD -
AED 3.672499
AFN 63.49745
ALL 82.633029
AMD 367.81347
ANG 1.790403
AOA 916.999952
ARS 1461.505699
AUD 1.441639
AWG 1.8
AZN 1.715562
BAM 1.715644
BBD 2.014246
BDT 122.861805
BGN 1.69088
BHD 0.3772
BIF 2987.24539
BMD 1
BND 1.295549
BOB 6.92556
BRL 5.173098
BSD 1.000105
BTN 94.687626
BWP 13.599361
BYN 2.808821
BYR 19600
BZD 2.011333
CAD 1.418805
CDF 2264.999622
CHF 0.80976
CLF 0.023111
CLP 909.649786
CNY 6.7748
CNH 6.78915
COP 3441.24
CRC 453.69217
CUC 1
CUP 26.5
CVE 96.725381
CZK 21.24805
DJF 178.090844
DKK 6.561625
DOP 58.536115
DZD 133.598219
EGP 49.725799
ERN 15
ETB 161.234408
EUR 0.87784
FJD 2.24285
FKP 0.754878
GBP 0.75675
GEL 2.645014
GGP 0.754878
GHS 11.225636
GIP 0.754878
GMD 72.999986
GNF 8763.311637
GTQ 7.629858
GYD 209.231741
HKD 7.84001
HNL 26.757135
HRK 6.615901
HTG 130.75668
HUF 311.258997
IDR 17921
ILS 2.996975
IMP 0.754878
INR 94.746197
IQD 1310.110704
IRR 1374999.999746
ISK 126.289781
JEP 0.754878
JMD 157.423814
JOD 0.708981
JPY 161.541504
KES 129.449525
KGS 87.450353
KHR 4014.105511
KMF 430.999706
KPW 900.00035
KRW 1536.210323
KWD 0.30902
KYD 0.833436
KZT 486.473447
LAK 22146.685497
LBP 89557.448376
LKR 334.602361
LRD 182.011965
LSL 16.491476
LTL 2.95274
LVL 0.60489
LYD 6.417656
MAD 9.360252
MDL 17.606449
MGA 4178.106825
MKD 54.12869
MMK 2099.387374
MNT 3579.000015
MOP 8.07637
MRU 39.722981
MUR 47.960227
MVR 15.460471
MWK 1734.153231
MXN 17.485902
MYR 4.140497
MZN 63.899865
NAD 16.491476
NGN 1368.395506
NIO 36.798891
NOK 9.7818
NPR 151.500026
NZD 1.761385
OMR 0.384502
PAB 1.000105
PEN 3.385323
PGK 4.386042
PHP 61.243499
PKR 278.148213
PLN 3.759275
PYG 6096.517967
QAR 3.645646
RON 4.606095
RSD 103.033017
RUB 74.553283
RWF 1466.604677
SAR 3.754291
SBD 8.065041
SCR 14.05647
SDG 600.500902
SEK 9.70755
SGD 1.295885
SHP 0.746601
SLE 24.749695
SLL 20969.503664
SOS 571.588975
SRD 37.4305
STD 20697.981008
STN 21.491605
SVC 8.751031
SYP 110.532098
SZL 16.486254
THB 33.201501
TJS 9.275777
TMT 3.51
TND 2.960315
TOP 2.40776
TRY 46.47955
TTD 6.79047
TWD 31.661499
TZS 2625.232026
UAH 44.892717
UGX 3660.590537
UYU 40.114211
UZS 12015.842175
VES 616.865275
VND 26325
VUV 118.758526
WST 2.756325
XAF 575.410972
XAG 0.016117
XAU 0.000243
XCD 2.70255
XCG 1.8024
XDR 0.713895
XOF 575.410972
XPF 104.61587
YER 238.649784
ZAR 16.483897
ZMK 9001.192558
ZMW 17.940666
ZWL 321.999592
  • CMSC

    -0.2100

    22.16

    -0.95%

  • BCC

    -2.1200

    72.54

    -2.92%

  • BP

    0.6800

    39.78

    +1.71%

  • GSK

    0.0700

    50.74

    +0.14%

  • CMSD

    -0.2100

    22.08

    -0.95%

  • RBGPF

    -0.2700

    60.34

    -0.45%

  • RIO

    -0.7200

    99.36

    -0.72%

  • NGG

    1.5300

    80.97

    +1.89%

  • BCE

    -0.6300

    22.65

    -2.78%

  • BTI

    -0.0100

    58.9

    -0.02%

  • RYCEF

    0.2300

    18.63

    +1.23%

  • JRI

    -0.0200

    12.65

    -0.16%

  • VOD

    -0.1800

    14.12

    -1.27%

  • RELX

    -0.3500

    30.83

    -1.14%

  • AZN

    1.5000

    176.43

    +0.85%

Frenchman rewarded for lifetime of research into narcolepsy
Frenchman rewarded for lifetime of research into narcolepsy / Photo: © AFP

Frenchman rewarded for lifetime of research into narcolepsy

Emmanuel Mignot is one of the world's leading experts on narcolepsy, a sleep disorder that he finds both "strange" and "fascinating."

Text size:

The French-born Mignot has dedicated his life to studying the causes of narcolepsy and shedding light on one of the great biological mysteries -- sleep.

His discovery of the genetic and molecular causes of the disorder led to his receiving a prestigious Breakthrough Prize on Thursday along with Japan's Masashi Yanagisawa, who made related findings around the same time.

Because of their discoveries, new treatments for narcolepsy -- which causes people to suddenly fall asleep -- and other sleep disorders are being developed.

About one in every 2,000 people suffers from narcolepsy. Some may experience catalepsy -- a sudden trance-like state.

"I am quite proud because what I have discovered is making an enormous difference for my patients," Mignot said in a telephone interview with AFP. "It's the best reward that one could receive."

The 63-year-old Mignot is a sleep researcher at Stanford University in California.

Thirty years ago, when he was a medical student, Mignot fulfilled his military service requirements in France by coming to Stanford to study a French-made drug that was being used to treat narcolepsy.

At the time, he said, the disease was "virtually unknown" and no one was actively studying it.

He became "completely fascinated."

"I told myself it's incredible, this disease, people fall asleep all the time, we have no idea why, and if we could discover the cause we might understand something new about sleep."

Stanford was already home to a renowned sleep center and its laboratory housed narcoleptic dogs, which Mignot began studying in an effort to find a genetic cause of the disease.

Genome sequencing was very primitive at that time and "everybody told me I was crazy," said Mignot, who currently has an adopted narcoleptic dog called Watson.

"I thought it would take a few years and it ended up taking 10."

In 1999, Mignot found a mutation in the genome of narcoleptic dogs. It was located on membrane receptors in the brain that respond to molecules outside the cell, similar to a lock and a key.

- 'Remake a key' -

The Japanese scientist Yanagisawa, meanwhile, had been studying orphan receptors -- receptors of unknown function -- in mice.

He discovered that a molecule that he named orexin binds to the same receptor Mignot detected as abnormal in dogs.

Mice who were deprived of orexin developed narcolepsy.

Mignot immediately began research on human subjects and found that orexin levels in the brain of narcolepsy patients were zero.

Normally, the molecule is produced in great quantities during the day, especially in the evening, allowing one to fight fatigue.

"You don't make a discovery like this twice in your life," Mignot said. "We found the cause of a disease.

"The advantage, is that we can remake a key," he said, referring to orexin.

For the moment, most patients are treated with a combination of powerful sedatives to help them sleep more soundly and amphetamines to keep them awake during the day.

Mignot said tests using a drug that mimics orexin have been "really miraculous."

Patients are fully awake and "transformed."

The challenge is to develop the right dose to be delivered at the right time.

Several companies, including Takeda of Japan, are working on it, and drugs could be authorized in the next few years.

They could be applied to other patients -- people suffering from depression, for example -- who have difficulty waking up, or to those in a coma.

Mignot meanwhile is studying whether narcolepsy may be caused by a flu virus.

The body's immune system may be confusing a flu virus with the cells that produce orexin and T-cells that fight infection are attacking them as a result.

"I've become interested in how the immune system works in the brain," a field he said is "beginning to explode."

As for sleep, Mignot remains fascinated by it even if he has uncovered one of the great mysteries.

"What is it that sleep does that it is so important that we have to do it every day?" he asked. "It's true that we still don't know."

T.Harrison--TFWP